Pegylated Interferon-Alpha-2A
Breast Neoplasm
BriaCell Therapeutics CorporationPhase 3Active
CCC
52/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 37/ 100
- Competitive Position
- 89/ 100
Competitive context
39 Active assets in the Breast Neoplasm cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Inno-206 Merck Sharp & Dohme LLC | Phase 2 | BB |
Zofran Umeå University | Phase 4 | BB |
Sv-Br-1-Gm BriaCell Therapeutics Corporation | Phase 3 | BB |
ROPIVACAINE Karlstad Central Hospital | Phase 3 | BB |
FILGRASTIM National Cancer Institute (NCI) | Phase 2 | BB |
View all 50 →
Same molecule, other indications
Pegylated Interferon-Alpha-2A is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →